---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-025102"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-06-25T23:59:59+00:00"
generated_at: "2026-06-01T02:13:47.756340+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics updates Nasdaq compliance status after $7.5M private placement; hearing June 27

## Summary
- Received Nasdaq deficiency notice on May 16, 2024 for failing to meet $2.5M equity requirement.
- Completed $7.5M private placement on June 10, 2024; believes it now meets equity requirement.
- Hearing before Nasdaq Panel scheduled June 27, 2024; decision expected within 30 days.
- Company acknowledges it will need additional equity capital to maintain ongoing compliance.
- Risk of delisting if unable to demonstrate compliance; could materially affect stock price.

## SEC filing metadata
- accession: 0001493152-24-025102
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-06-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224025102/0001493152-24-025102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224025102/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-025102
- JSON: https://secwatch.observer/filing/0001493152-24-025102.json
- Plain text: https://secwatch.observer/filing/0001493152-24-025102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.